
-
Sanofi NasdaqGS:SNY Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Location: 46, avenue de la Grande Armée, Paris, 75017, France | Website: https://www.sanofi.com | Industry: Drug Manufacturers - General | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
76.33B
Cash
7.556B
Avg Qtr Burn
N/A
Short % of Float
0.33%
Insider Ownership
0.00%
Institutional Own.
10.49%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ALTUVIIIO™ (Efanesoctocog alfa) Details Hemophilia | Approved Quarterly sales | |
Dupixent Details Chronic obstructive pulmonary disease | Approved Quarterly sales | |
Dupixent Details Chronic spontaneous urticaria | Approved Quarterly sales | |
Qfitlia™ (fitusiran) Details Hemophilia | Approved Quarterly sales | |
Beyfortus™ (Nirsevimab- alip) Details Respiratory syncytial virus | Approved Quarterly sales | |
Dupixent Details Eosinophilic Esophagitis | Approved Quarterly sales | |
TZIELD™ (PRV-031) (Teplizumab) Details Type 1 diabetes, Diabetes | Approved Quarterly sales | |
Dupixent Details Chronic rhinosinusitis with nasal polyps | Approved Quarterly sales | |
Sarclisa® Details Multiple myeloma, Cancer | Approved Quarterly sales | |
Tolebrutinib Details Multiple sclerosis, Autoimmune disease | BLA Submission | |
ExPEC9V vaccine Details Invasive Extraintestinal Pathogenic Escherichia Coli Disease | Phase 3 Data readout | |
Amlitelimab Details Atopic dermatitis | Phase 3 Data readout | |
Tzield (Teplizumab) Details Type 1 diabetes, Diabetes | Phase 3 Update | |
Frexalimab Details Autoimmune disease, Multiple sclerosis | Phase 3 Update | |
Ordesekimab (PRV-015) (anti-IL-15) Details Celiac disease, Immune Disorders | Phase 2b Data readout | |
INBRX-101 (AAT-Fc fusion protein) Details Genetic disorder, Severe alpha-1 antitrypsin deficiency, Rare genetic disease, Emphysema due to Alpha-1 Antitrypsin Deficiency | Phase 2 Data readout | |
PRV-3279 Details Systemic lupus erythematosus, Autoimmune disease | Phase 2a Data readout |